Rakovina Therapeutics continues to make progress as company provides corporate update
September 13, 2023 at 01:31 pm EDT
Share
(via NewsDirect)
Rakovina Therapeutics Executive Chairman Jeffery Bacha joined Steve Darling from Proactive to discuss the company's corporate highlights as part of its second-quarter financial report.
Bacha highlighted several significant developments for the company during this period: including a publication in the Journal of Clinical Oncology.
Rakovina Therapeutics published a paper in the Journal of Clinical Oncology describing pre-clinical data for its lead pre-clinical candidate, kt-3283. This data demonstrates the potential of kt-3283 to treat cancers that are resistant to first-generation PARP inhibitors.
This development is crucial as it suggests that Rakovina's compound could address unmet medical needs in the treatment of various treatment-resistant cancers, including Ewing sarcoma.
Bacha also said the company presented at the American Association of Cancer Research. The company presented new preclinical in vitro and in vivo data at the annual meeting of the American Association of Cancer Research. This data demonstrated the potential of Rakovina's kt-3000 series in treating treatment-resistant Ewing sarcoma, a rare childhood tumor.
The kt-3000 series is a novel class of DNA-damage response inhibitors designed to selectively inhibit two important anti-cancer targets: poly(ADP) ribose polymerase (PARP) and histone deacetylase (HDAC).
These developments reflect Rakovina Therapeutics' commitment to advancing innovative treatments for challenging and resistant cancers. The company's research and progress in the field of cancer therapy offer hope for patients and represent significant strides in addressing unmet medical needs.
Contact Details
Proactive Investors
+1 604-688-8158
na-editorial@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.
Copyright (c) 2023 TheNewswire - All rights reserved., source Press Releases
Rakovina Therapeutics Inc. is a Canada-based biopharmaceutical company. The Company is engaged in advancing cancer therapies based on deoxyribonucleic acid (DNA)-damage response technologies. The Company has a pipeline of DNA-damage response inhibitors to advance one or more drug candidates into human clinical trials and obtain marketing approval for cancer therapeutics. The Companyâs research programs include kt-2000, kt-3000 and kt-4000. The kt-2000 next generation PARP-inhibitors. The kt-3000 class drug candidates are rationally designed to overcome treatment resistance by selectively downregulating DNA double-strand (DSB) repair mechanisms while enhancing PARP inhibitor activity. The kt-4000 series lead candidates release a potent methylation agent causing damage to a tumor cellâs DNA while also inhibiting DNA-damage repair mechanisms to cancer cell death.
RAKOVINA THERAPEUTICS INC. 
